Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00135434 · ClinicalTrials.gov registry record · Phase 1
Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism
A Phase 1 study of HIV Infections, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00135434 is a Phase 1 study of HIV Infections that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 25 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00135434, a Phase 1 study of HIV Infections, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examined the effects of two commonly prescribed HIV drugs on the way the body metabolizes glucose, insulin and fat.
Conditions Studied
Interventions
- DRUG Atazanavir/Ritonavir/Lopinavir/ritonavir
Study Locations (1)
New Jersey
- Clinical Pharmacology Unit, Bristol-Myers Squibb Company - Hamilton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00135434
The ClinicalTrials.gov registry entry for NCT00135434 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Atazanavir/Ritonavir/Lopinavir/ritonavir is the first listed.
NCT00135434 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00135434 about?
NCT00135434 is a clinical study titled "Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism". This study examined the effects of two commonly prescribed HIV drugs on the way the body metabolizes glucose, insulin and fat.
What is the current status of trial NCT00135434?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2004-09. Estimated completion is 2005-06.
What conditions does trial NCT00135434 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00135434?
The interventions under investigation include: Atazanavir/Ritonavir/Lopinavir/ritonavir (DRUG).
Who is sponsoring clinical trial NCT00135434?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00135434 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.